Cambridge Healthtech Institute’s 17th Annual

Target Identification and Validation

Part 1: Proteomics-Based Target Discovery

September 16-17, 2020

Part 2: Genomics-Based Target Discovery

September 17-18, 2020


Finding novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry. It also remains a formidable challenge and companies continue to invest a lot of time and resources in identifying and validating targets that will yield viable drugs. How are genomics and proteomics helping overcome some of the challenges in target discovery today? What new tools and strategies are being employed and how well are they working? What’s being done to adequately validate the targets once they are identified? What efforts are being taken to go after difficult or “undruggable” targets? Cambridge Healthtech Institute’s conference on Target Identification and Validation will bring together leading experts to discuss some of these critical issues. This is an unique opportunity to meet and network with biologists and screening groups from around the world to share ideas and best practices.


Who should attend: Scientists in Molecular and Cellular Biology, Discovery Biology, Target Discovery, Target Identification and Validation, Chemical Biology, Proteomics, Genetics, Systems Biology, Assay Development, High Throughput Screening, Molecular Screening, Discovery Informatics, and Computational Biology.     


Part 1:

Besides target identification, target deconvolution and validation are also equally challenging and remain important bottlenecks in drug discovery. Chemical biology, particularly chemoproteomics and other mass spectrometry-based tools and assays are playing an important role in identifying, evaluating and priortizing new drug targets. The first part of the Target Identification and Validation conference focuses on Proteomics-Based Target Discovery that leverages these new chemical probes, assays and screening tools being developed.     


Coverage will include, but is not limited to:

  • New methodologies for target deconvolution and validation of small molecules and peptides
  • Applications of chemoproteomic strategies: affinity assays, CETSA, activity-based protein profiling
  • Design and use of new chemical probes and assays for proteomics-based target discovery
  • Biophysical and cellular assays for studying target engagement
  • Phenotypic versus target-based screening approaches
  • Expoliting protein-protein interaction networks for target identification
  • Chemical proteomics for emerging drug targets – transcription factors, epigenetic readers, RNA, transporters     


Part 2:

The second part of the Target Identification and Validation conference focuses on Genomics-Based Target Discovery. It includes applications of RNAi, CRISPR, chemical genetics, single cell sequencing and other genomics-based tools to identify and validate new cellular pathways and drug targets. Complementary use of these technologies integrated with emerging data analysis and AI/ML approaches will also be discussed.     


Coverage will include, but is not limited to:

  • Use of CRISPR, CRISPRi/a, and chemical genomic screens for finding novel targets
  • Functional genomics approaches for in vitro and in vivo target screening
  • Use of whole genome sequencing, single cell sequencing, GWAS for target screening
  • Using data mining and visualization tools to identify, evaluate and prioritize drug targets
  • Exploring artificial intelligence and machine learning tools for target identification and characterization
  • Using databases and pathway analysis for associating targets and diseases
  • Case studies on how to deconvolute and prioritize druggable targets from screening hits       


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is February 26, 2020.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute



For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286